)
)
)
Newron is a biopharmaceutical company, headquartered in Bresso near Milan, Italy, the Company has a strong track record of advancing neuroscience-based treatments from discovery to market. Newron’s lead compound, evenamide, is a first-in-class glutamate modulator and has the potential to be the first add-on therapy for TRS and for poorly responding patients with schizophrenia. Evenamide is currently developed in the global pivotal ENIGMA-TRS Phase III development program. Clinical trial results to date demonstrate the benefits of this drug candidate in the TRS as well as poorly responding patient population, with significant improvements across key efficacy measures increasing over time, as well as a favorable safety profile, which is uncommon for available antipsychotic medications. Newron has signed development and commercialization agreements for evenamide with EA Pharma (a subsidiary of Eisai) for Japan and other Asian territories, as well as Myung In Pharm for South Korea.
Year Founded
1999
Next catalyst (value inflection) update
na
Expected time of next catalyst update
na
City
Bresso
Country
Italy
Company CEO or top company official
Stefan Weber
Development Phase of Primary Product
Phase III
Exchange
SIX/XETRA
Lead Product in Development
evenamide
Therapeutic Area
CNS/Neurological
Ticker
NWRN/NP5
Website
https://www.newron.com/
){kind=logo}
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
